Virginia Olivia Volpe, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 5 | 2023 | 1356 | 1.430 |
Why?
|
| Neutropenia | 1 | 2023 | 893 | 0.600 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 1073 | 0.590 |
Why?
|
| SEER Program | 1 | 2021 | 1510 | 0.540 |
Why?
|
| Anemia | 1 | 2023 | 1505 | 0.450 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 3531 | 0.340 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1572 | 0.310 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 21 | 0.220 |
Why?
|
| Phosphoproteins | 2 | 2022 | 2449 | 0.220 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 97 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 5584 | 0.190 |
Why?
|
| Melanoma | 1 | 2017 | 5547 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 5751 | 0.150 |
Why?
|
| Azetidines | 1 | 2017 | 142 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 996 | 0.130 |
Why?
|
| Oximes | 1 | 2017 | 309 | 0.130 |
Why?
|
| Prognosis | 5 | 2022 | 29264 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2017 | 383 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13678 | 0.120 |
Why?
|
| Mutation | 4 | 2022 | 29981 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1806 | 0.110 |
Why?
|
| Pyridones | 1 | 2017 | 738 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2017 | 855 | 0.100 |
Why?
|
| Imidazoles | 1 | 2017 | 1201 | 0.100 |
Why?
|
| Disease Progression | 3 | 2022 | 13364 | 0.090 |
Why?
|
| Survival Rate | 2 | 2021 | 12802 | 0.090 |
Why?
|
| Indoles | 1 | 2017 | 1839 | 0.080 |
Why?
|
| Piperidines | 1 | 2017 | 1630 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11626 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 1622 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2017 | 1963 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 2042 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2755 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2022 | 12165 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2022 | 262 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2022 | 666 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 9300 | 0.050 |
Why?
|
| Humans | 8 | 2023 | 752741 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2021 | 10252 | 0.040 |
Why?
|
| Aged | 4 | 2021 | 165629 | 0.040 |
Why?
|
| Risk Factors | 1 | 2023 | 73094 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2019 | 1604 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 1595 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 4794 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 3404 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 58361 | 0.020 |
Why?
|
| Comorbidity | 1 | 2019 | 10450 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 57267 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5469 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 39223 | 0.010 |
Why?
|
| Male | 3 | 2021 | 354311 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 40939 | 0.010 |
Why?
|
| Female | 3 | 2021 | 385090 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 23554 | 0.010 |
Why?
|
| Middle Aged | 2 | 2021 | 216054 | 0.010 |
Why?
|
| Adult | 2 | 2021 | 216658 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 78758 | 0.010 |
Why?
|